Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mental Disorders | 6 | 2025 | 377 | 2.100 |
Why?
|
| Psychometrics | 4 | 2025 | 350 | 1.240 |
Why?
|
| Nutrition Surveys | 13 | 2025 | 263 | 0.930 |
Why?
|
| Self Efficacy | 2 | 2025 | 211 | 0.860 |
Why?
|
| Lactobacillus | 1 | 2020 | 22 | 0.640 |
Why?
|
| Resilience, Psychological | 1 | 2021 | 89 | 0.630 |
Why?
|
| Adult | 38 | 2025 | 13458 | 0.620 |
Why?
|
| Probiotics | 1 | 2020 | 37 | 0.610 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3077 | 0.610 |
Why?
|
| Middle Aged | 35 | 2025 | 11819 | 0.560 |
Why?
|
| Glaucoma | 3 | 2024 | 98 | 0.560 |
Why?
|
| United States | 23 | 2025 | 5072 | 0.540 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 49 | 0.530 |
Why?
|
| Male | 40 | 2025 | 22779 | 0.530 |
Why?
|
| Female | 46 | 2025 | 24018 | 0.520 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 84 | 0.510 |
Why?
|
| Liver | 1 | 2020 | 503 | 0.510 |
Why?
|
| Prevalence | 15 | 2024 | 1597 | 0.500 |
Why?
|
| Humans | 53 | 2025 | 42163 | 0.480 |
Why?
|
| Aged | 28 | 2025 | 7982 | 0.480 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 181 | 0.480 |
Why?
|
| Young Adult | 16 | 2025 | 4936 | 0.460 |
Why?
|
| Aging | 2 | 2020 | 764 | 0.450 |
Why?
|
| Health Transition | 1 | 2014 | 4 | 0.440 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 729 | 0.430 |
Why?
|
| Oxidative Stress | 2 | 2020 | 990 | 0.430 |
Why?
|
| Factor Analysis, Statistical | 3 | 2025 | 157 | 0.420 |
Why?
|
| Population Surveillance | 2 | 2013 | 245 | 0.420 |
Why?
|
| Accidents, Traffic | 1 | 2013 | 46 | 0.410 |
Why?
|
| California | 14 | 2024 | 531 | 0.410 |
Why?
|
| Health Status Disparities | 3 | 2025 | 705 | 0.400 |
Why?
|
| Hospitalization | 3 | 2021 | 482 | 0.400 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 532 | 0.390 |
Why?
|
| Veterans | 2 | 2025 | 203 | 0.390 |
Why?
|
| Fatty Liver | 2 | 2025 | 71 | 0.390 |
Why?
|
| Reproducibility of Results | 4 | 2025 | 1058 | 0.380 |
Why?
|
| Exercise | 1 | 2017 | 674 | 0.360 |
Why?
|
| Brain Injuries | 1 | 2013 | 133 | 0.360 |
Why?
|
| Brain | 1 | 2020 | 1452 | 0.360 |
Why?
|
| Multiple Sclerosis | 2 | 2024 | 48 | 0.350 |
Why?
|
| Albuminuria | 3 | 2020 | 78 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 744 | 0.310 |
Why?
|
| Intraocular Pressure | 3 | 2024 | 133 | 0.300 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 573 | 0.290 |
Why?
|
| Length of Stay | 2 | 2021 | 231 | 0.280 |
Why?
|
| Self-Injurious Behavior | 2 | 2018 | 25 | 0.270 |
Why?
|
| Birth Weight | 1 | 2007 | 94 | 0.260 |
Why?
|
| Adolescent | 16 | 2024 | 5950 | 0.260 |
Why?
|
| Retrospective Studies | 11 | 2024 | 2485 | 0.240 |
Why?
|
| Suicide, Attempted | 2 | 2018 | 104 | 0.240 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2025 | 7 | 0.230 |
Why?
|
| Age Factors | 5 | 2021 | 1139 | 0.220 |
Why?
|
| Hospital Mortality | 3 | 2021 | 206 | 0.220 |
Why?
|
| Glaucoma, Neovascular | 1 | 2024 | 3 | 0.220 |
Why?
|
| Academies and Institutes | 1 | 2024 | 39 | 0.220 |
Why?
|
| Morbidity | 4 | 2017 | 97 | 0.210 |
Why?
|
| Ophthalmology | 1 | 2024 | 34 | 0.210 |
Why?
|
| Employment | 1 | 2024 | 83 | 0.210 |
Why?
|
| Mexican Americans | 3 | 2025 | 224 | 0.210 |
Why?
|
| Sex Factors | 5 | 2021 | 1008 | 0.210 |
Why?
|
| Vision Disorders | 1 | 2024 | 61 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 90 | 0.200 |
Why?
|
| Xylans | 2 | 2016 | 26 | 0.200 |
Why?
|
| Activities of Daily Living | 1 | 2024 | 136 | 0.200 |
Why?
|
| Stomach Neoplasms | 2 | 2016 | 228 | 0.200 |
Why?
|
| Niacin | 1 | 2023 | 23 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2017 | 1729 | 0.200 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 708 | 0.190 |
Why?
|
| Neck Injuries | 2 | 2019 | 10 | 0.190 |
Why?
|
| Self Concept | 1 | 2023 | 170 | 0.190 |
Why?
|
| Vision, Low | 1 | 2022 | 13 | 0.190 |
Why?
|
| Psychotic Disorders | 1 | 2023 | 69 | 0.190 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2023 | 82 | 0.190 |
Why?
|
| Iron | 2 | 2015 | 247 | 0.190 |
Why?
|
| Registries | 1 | 2024 | 431 | 0.180 |
Why?
|
| Rural Population | 1 | 2024 | 352 | 0.180 |
Why?
|
| Education, Distance | 1 | 2022 | 46 | 0.180 |
Why?
|
| Hospital Charges | 1 | 2021 | 15 | 0.180 |
Why?
|
| Risk | 3 | 2017 | 289 | 0.170 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 134 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2021 | 91 | 0.160 |
Why?
|
| Risk Factors | 10 | 2024 | 3942 | 0.160 |
Why?
|
| Infant, Newborn | 3 | 2014 | 960 | 0.160 |
Why?
|
| Head Protective Devices | 1 | 2019 | 11 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 2803 | 0.160 |
Why?
|
| Injury Severity Score | 1 | 2019 | 69 | 0.160 |
Why?
|
| Craniocerebral Trauma | 1 | 2019 | 22 | 0.160 |
Why?
|
| Bicycling | 1 | 2019 | 19 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 164 | 0.160 |
Why?
|
| Lipid Peroxidation | 1 | 2020 | 141 | 0.150 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 287 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 138 | 0.150 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 2019 | 18 | 0.150 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 29 | 0.150 |
Why?
|
| Pregnancy | 7 | 2017 | 1737 | 0.150 |
Why?
|
| Mental Health | 2 | 2024 | 363 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2025 | 547 | 0.140 |
Why?
|
| Comorbidity | 4 | 2025 | 725 | 0.140 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2019 | 199 | 0.140 |
Why?
|
| Patient Admission | 1 | 2017 | 50 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 191 | 0.120 |
Why?
|
| Stomach | 1 | 2016 | 50 | 0.120 |
Why?
|
| Automobile Driving | 1 | 2016 | 24 | 0.120 |
Why?
|
| Dementia, Vascular | 1 | 2016 | 36 | 0.120 |
Why?
|
| Kidney Diseases | 3 | 2006 | 170 | 0.120 |
Why?
|
| Intention | 1 | 2016 | 103 | 0.120 |
Why?
|
| Inpatients | 1 | 2016 | 78 | 0.120 |
Why?
|
| Databases, Factual | 5 | 2019 | 336 | 0.110 |
Why?
|
| Protective Agents | 1 | 2015 | 26 | 0.110 |
Why?
|
| Child | 4 | 2021 | 3381 | 0.110 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 2014 | 1 | 0.110 |
Why?
|
| Obstetrical Forceps | 1 | 2014 | 3 | 0.110 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2014 | 5 | 0.110 |
Why?
|
| Birth Injuries | 1 | 2014 | 7 | 0.110 |
Why?
|
| Medical History Taking | 1 | 2014 | 37 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 16 | 0.110 |
Why?
|
| Shock, Septic | 1 | 2014 | 19 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 27 | 0.110 |
Why?
|
| Incidence | 4 | 2023 | 1054 | 0.100 |
Why?
|
| Pregnancy in Diabetics | 1 | 2013 | 8 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 239 | 0.100 |
Why?
|
| Vitamin D Deficiency | 2 | 2005 | 107 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 12 | 0.100 |
Why?
|
| Eclampsia | 1 | 2013 | 13 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2014 | 99 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 13 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 137 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2013 | 23 | 0.100 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 825 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 55 | 0.100 |
Why?
|
| Hypertension | 4 | 2016 | 823 | 0.100 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 1221 | 0.100 |
Why?
|
| Infant | 2 | 2013 | 1143 | 0.090 |
Why?
|
| Apoptosis | 2 | 2019 | 1541 | 0.090 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 2012 | 7 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2014 | 386 | 0.090 |
Why?
|
| Los Angeles | 2 | 2017 | 390 | 0.090 |
Why?
|
| Medicare | 3 | 2023 | 326 | 0.090 |
Why?
|
| Mice | 2 | 2020 | 6490 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2013 | 1516 | 0.090 |
Why?
|
| Patient Discharge | 3 | 2007 | 131 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 16695 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2018 | 587 | 0.080 |
Why?
|
| Health Surveys | 3 | 2007 | 401 | 0.080 |
Why?
|
| Reference Values | 2 | 2007 | 207 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 158 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 680 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 972 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 211 | 0.070 |
Why?
|
| Cholesterol, LDL | 2 | 2024 | 73 | 0.070 |
Why?
|
| Parity | 1 | 2007 | 60 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2007 | 24 | 0.070 |
Why?
|
| Hypoglycemia | 1 | 2007 | 24 | 0.060 |
Why?
|
| Gestational Age | 1 | 2007 | 195 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2007 | 108 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2007 | 143 | 0.060 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2016 | 7 | 0.060 |
Why?
|
| Vitamin D | 1 | 2007 | 196 | 0.060 |
Why?
|
| Pregnancy, Ectopic | 1 | 2005 | 15 | 0.060 |
Why?
|
| Pregnancy Outcome | 2 | 2017 | 92 | 0.060 |
Why?
|
| Skilled Nursing Facilities | 1 | 2005 | 20 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2016 | 282 | 0.060 |
Why?
|
| Hip Fractures | 1 | 2005 | 29 | 0.060 |
Why?
|
| Lipids | 1 | 2006 | 256 | 0.060 |
Why?
|
| Population Groups | 1 | 2005 | 59 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 285 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2006 | 164 | 0.050 |
Why?
|
| Trabeculectomy | 1 | 2024 | 32 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2024 | 47 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2025 | 512 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2024 | 117 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2005 | 187 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2005 | 208 | 0.050 |
Why?
|
| Poverty | 1 | 2006 | 395 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 81 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2022 | 57 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2022 | 56 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 487 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 144 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 438 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 92 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 84 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2019 | 64 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2002 | 662 | 0.040 |
Why?
|
| Obesity | 2 | 2007 | 1131 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2006 | 541 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2002 | 916 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2018 | 61 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2018 | 44 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 845 | 0.030 |
Why?
|
| Poisoning | 1 | 2017 | 13 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 268 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 2017 | 22 | 0.030 |
Why?
|
| DNA Damage | 1 | 2019 | 358 | 0.030 |
Why?
|
| Triglycerides | 2 | 2007 | 146 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 224 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 249 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2016 | 76 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 64 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 253 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 226 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 152 | 0.030 |
Why?
|
| Attitude | 1 | 2016 | 108 | 0.030 |
Why?
|
| Free Radicals | 1 | 2015 | 72 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 167 | 0.030 |
Why?
|
| Vacuum | 1 | 2014 | 6 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 452 | 0.030 |
Why?
|
| Postpartum Hemorrhage | 1 | 2014 | 19 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 638 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 48 | 0.030 |
Why?
|
| Cichlids | 1 | 2013 | 5 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 448 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 39 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2013 | 27 | 0.030 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 14 | 0.030 |
Why?
|
| Diet | 1 | 2019 | 810 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1420 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2016 | 456 | 0.020 |
Why?
|
| Audiometry | 1 | 2012 | 3 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 353 | 0.020 |
Why?
|
| Stroke | 1 | 2016 | 348 | 0.020 |
Why?
|
| Ethiodized Oil | 1 | 2010 | 3 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2010 | 6 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 31 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 48 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2010 | 34 | 0.020 |
Why?
|
| Students | 1 | 2016 | 617 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1001 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 305 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2010 | 95 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1112 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 366 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 150 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 439 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2598 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 837 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1586 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 3701 | 0.020 |
Why?
|
| Ethanol | 1 | 2010 | 221 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 36 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 58 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 48 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2007 | 64 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 99 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 195 | 0.020 |
Why?
|
| Medicaid | 1 | 2007 | 138 | 0.010 |
Why?
|
| Education | 1 | 2005 | 60 | 0.010 |
Why?
|
| Cholesterol | 1 | 2006 | 230 | 0.010 |
Why?
|
| Social Class | 1 | 2007 | 286 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 48 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 210 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 1574 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 249 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 363 | 0.010 |
Why?
|
| Indians, North American | 1 | 2005 | 179 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2002 | 53 | 0.010 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2005 | 188 | 0.010 |
Why?
|
| Minority Groups | 1 | 2005 | 663 | 0.010 |
Why?
|